Abstract
Dupilumab treatment in children aged 6–11 years with severe atopic dermatitis is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have